Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Novo Nordisk's Wegovy launch in new markets will be slower due to high demand
05:31am, Tuesday, 20'th Jun 2023
Novo Nordisk's launch of obesity drug Wegovy in most of Europe will be slower than planned and the drug will likely not be sold in developing nations for a very long time, executives said on Tuesday,
Novo Nordisk: Wegovy launch in new markets slower due to high demand
04:25am, Tuesday, 20'th Jun 2023
Novo Nordisk is taking the launch of its obesity drug Wegovy "a little slower than planned" in new markets due to higher than expected demand in the three countries where it is currently sold, an exec
Hit Wegovy weight-loss drug on track for $4 billion in U.S. sales despite supply constraints, analyst says
03:23am, Tuesday, 20'th Jun 2023
The hit Wegovy weight-loss drug is on track for sales of over $4 billion this year in the U.S. alone, despite its manufacturer Novo Nordisk struggling to keep up with demand.
This Biotech Is Developing The Next Ozempic. Should You Buy It?
08:00am, Friday, 16'th Jun 2023
Structure Therapeutics is working on therapies for diabetes and obesity. Its efforts are still early-stage, but it has plenty of cash to keep going.
Five things to know about berberine, the supplement being compared to the weight-loss drug Ozempic
03:32pm, Thursday, 15'th Jun 2023
By now, most Americans have heard of Ozempic, Mounjaro and Wegovy, the Type 2 diabetes drugs that are also helping people lose weight — in some cases, significant amounts.
2 Market-Beating Stocks With More Upside Potential
08:45am, Thursday, 15'th Jun 2023
Eli Lilly and Novo Nordisk are among the leaders in diabetes and obesity care. Both companies will continue to makes important strides in these two areas.
Better Long-Term Buy: AbbVie or Novo Nordisk?
08:05am, Saturday, 10'th Jun 2023
Novo Nordisk is forecasting revenue and operating profit growth this year. AbbVie said it expects to return to revenue growth in 2025.
3 Reasons Why Growth Investors Shouldn't Overlook Novo Nordisk (NVO)
01:57pm, Friday, 09'th Jun 2023
Novo Nordisk (NVO) could produce exceptional returns because of its solid growth attributes.
Why Novo Nordisk Stock Bumped Higher Today
05:13pm, Tuesday, 06'th Jun 2023
A bullish pundit reiterated his unambiguous buy recommendation on the company. He believes the share price could rise by nearly 30%.
Novartis Announces Positive Data on Breast Cancer Drug Kisqali
03:56pm, Monday, 05'th Jun 2023
Novartis' (NVS) Kisqali reduces the risk of recurrence by 25% among patients with early breast cancer.
Novo Nordisk (NVO) Gears Up to Acquire BIOCORP for 154M Euros
12:41pm, Monday, 05'th Jun 2023
Novo Nordisk (NVO) enters into negotiations to acquire a majority stake in BIOCORP, followed by a tender offer to acquire all remaining shares in BIOCORP for a total equity value of 154 million Euros.
Best Momentum Stocks to Buy for June 5th
11:10am, Monday, 05'th Jun 2023
VIPS, KOF and NVO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 5, 2023.
Is Novo Nordisk (NVO) Stock Outpacing Its Medical Peers This Year?
10:55am, Monday, 05'th Jun 2023
Here is how Novo Nordisk (NVO) and Roche Holding AG (RHHBY) have performed compared to their sector so far this year.
New Strong Buy Stocks for June 5th
09:10am, Monday, 05'th Jun 2023
NEM, KMT, VIPS, NVO and BAMXF have been added to the Zacks Rank #1 (Strong Buy) List on June 5, 2023.
Novo Nordisk in talks to buy controlling stake in Biocorp
08:40am, Monday, 05'th Jun 2023
Novo Nordisk NVO, -0.53% has entered into exclusive negotiations to acquire a controlling stake in French medical device maker Biocorp in a deal that values Biocorp at 154.4 million euros, or about $1
